The Centers for Disease Control and Prevention said human metapneumovirus – also known as HMPV – filled intensive care units with children and seniors this spring.

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The deal adds vaccine candidates for respiratory syncytial virus and human metapneumovirus to the French pharmaceutical group ...

Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory ...

(Reuters) -French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio ...

Maybe it was really a quadruple-demic. A little known and underappreciated virus called human metapneumovirus spiked in the US this spring just after RSV, influenza and Covid-19 died down.

No, there’s been a surge of the human metapneumovirus (HMPV). In fact, in mid-March, at the height of the surge, over 19% of all respiratory secretion specimens polymerase chain reaction ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

Human metapneumovirus is a virus discovered in 2001 that causes respiratory infection. It falls under the paramyxovirus umbrella, which is "a family of viruses known to cause a wide range of ...

Read: Cases of human metapneumovirus surge; What are the signs, symptoms of HMPV? 3. Just like RSV and the flu, HMPV can cause people to be admitted to intensive care units and can cause deadly ...

It's called human metapneumovirus (HMPV). "The symptoms are identical almost to influenza and respiratory syncytial virus," said Dr. Jorge Rodriguez, a board-certified internal medicine specialist.